UNSPSC 51143211: Lobeline hydrochloride

This classification denotes a nicotinic agonist with the molecular formula C22H27NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96J834CB88, chemically known as ethanone, 2-(6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenyl-, hydrochloride but more generally known as lobeline hydrochloride, which bears US NIH Compound Identifier 46202. European Medicines Agency schedules Lobeline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14389MIG.

Most nations, for tariff and trade purposes, schedule lobeline hydrochloride under HS 29399900 and SITC 54149. As of Q4 2014, LOBELINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1[C@@H](CCC[C@@H]1CC(=O)C2CCCCC2)C[C@@H](C3CCCCC3)O.CL.

UNSPSC 51143211 Lobeline hydrochloride is a Commodity code that nominally identifies a pharmaceutical alkaloid, but recent state and local solicitations under this code show a significant mismatch with the taxonomy designation. The single recent opportunity posted under the code — Seminole County, Florida's IFB60459723LAS — solicits Naloxone and Safe Drug Deactivation Systems, neither of which are lobeline hydrochloride or closely related compounds. The county procures these items to support community health initiatives, with vendors required to deliver quarterly shipments of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually to the Seminole County Community Health Building in Sanford, Florida. Bidders must submit electronic bids through the county's e-Procurement Portal, include all shipping and delivery costs in their pricing, provide drug-free workplace certification and E-Verify compliance documentation, and maintain workers' compensation, commercial general liability, and professional liability insurance.

Seminole County, Florida is the only issuing body with recent activity recorded under this code. The IFB posted on June 30, 2026, with a response deadline of July 26, 2023 (a date inconsistency in the source record itself), calls for fixed-fee pricing on a competitive bidding basis. The contract includes an initial two-year term with an optional one-year renewal and a three-month probationary period. The procurement may draw FEMA funding, introducing federal compliance obligations including adherence to the Clean Air Act and Federal Water Pollution Control Act. No explicit set-aside designations for disadvantaged enterprises are specified. This code shows minimal recent state and local activity and appears to be tagged inconsistently with actual procurement intent; activity in opioid-reversal pharmaceutical procurement may be better tracked under broader pharmaceutical or emergency-response supply codes.